Joint pain after decades of running — what's actually wearing
5 min read · Uplevel editorial
You've been running since your twenties. The knees and hips have been reliable — not always pain-free, not without the occasional tight morning after a long weekend, but fundamentally available. You've logged thousands of miles and your body has largely been a reasonable partner in this. Then somewhere in your forties, the conversation changed. A deep ache in the knee that lingers two days after a long run instead of resolving overnight. A hip flexor that used to release within the first mile and now doesn't fully let go until mile three, sometimes not at all. A stiffness in the morning that takes longer to work through than it used to. The signals are familiar enough that you know them, but they've acquired a persistence they didn't have before.
The medical response, when you finally bring it up, tends to land somewhere between "you've done a lot of mileage" — which is accurate and completely unhelpful — and an MRI, which may or may not match what you're feeling. The orthopedist might use the phrase "wear and tear." That phrase does real harm, not because it's entirely wrong but because it implies a trajectory — things that wear don't unwear — that forecloses the more useful question of what is actually happening at the tissue level and whether any of it is addressable.
The "wear and tear" framing conflates several things that are worth separating. Cartilage destruction in the classical osteoarthritis sense — the bone-on-bone endpoint that joint replacement addresses — is a different thing from the cumulative matrix changes that accumulate in active people in midlife. Most runners in their forties and fifties who are having these symptoms aren't at the endpoint. They're in a middle territory where cartilage and connective tissue have undergone real changes, where tendon and ligament architecture has shifted, where neuromuscular patterns have adapted over years in ways that load the joint differently — but where the situation is not fixed and the tissue is not inert. The MRI often shows either less than the symptoms predict, or degenerative findings that are real but don't fully explain the pain pattern. That gap between imaging and experience is informative. It means the story isn't purely structural.
Cartilage matrix quality changes with age and cumulative load in ways that imaging underestimates. Articular cartilage is avascular — it doesn't have a direct blood supply, it relies on diffusion through synovial fluid for nutrient delivery. This makes it slow to both degrade and to repair. The matrix quality — the proteoglycan content, the collagen organization, the hydration state — shifts with decades of loading, with declining GH and IGF-1 that normally support cartilage maintenance, and with the anabolic hormonal environment declining in this decade. The cartilage doesn't disappear; it becomes less resilient. Less able to absorb impact and distribute it efficiently. More prone to focal overload in patterns that produce the specific, location-consistent aching that longtime runners know.
Tendons and ligaments undergo their own structural changes. Collagen quality shifts with age — the ratio of Type I to Type III collagen changes, crosslinking increases, and the tissue becomes stiffer and less elastic. A tendon that absorbed the repetitive loading of running in your thirties by stretching and recoiling efficiently is absorbing the same loading in your forties through a different mechanical model. Tendinopathy in this decade often isn't classic inflammation — it's a matrix disorganization, a failure of the tendon's internal architecture to maintain the organized fibrillar structure that healthy load-bearing requires. This distinction matters because anti-inflammatory approaches (rest, NSAIDs) treat a process that isn't primarily inflammatory. They reduce symptoms without addressing what's actually happening in the tissue.
The neuromuscular picture is underappreciated. Running gait changes subtly and cumulatively over decades of adaptations to small injuries, to strength asymmetries, to the specific terrain and surfaces of a given running history. A right hip that was slightly protective after a minor adductor strain five years ago may have introduced a compensatory loading pattern that has been accumulating work in the ipsilateral knee ever since. Muscles that have become relatively weak or inhibited through years of repetitive one-plane motion — hip abductors, posterior chain structures — change how force is distributed across the joint during loading. The knee that's aching may be aching partly because the muscles that should be absorbing its load have been quietly failing at that job for years. The joint is paying a tax that the muscular system should be covering.
Early osteoarthritis — when imaging does show it — exists on a spectrum. The presence of osteophytes or cartilage thinning on an MRI is not a verdict. Many people carry degenerative findings on imaging without proportional pain, and others have significant pain alongside modest findings, because the relationship between structure and symptom is looser than the scan implies.
What follows from all of this is that the most useful interventions are the ones that change how load reaches the joint, and here the evidence points most clearly at targeted strength training. Building the posterior chain — glutes and hamstrings — along with the hip abductors and single-leg stability does not rebuild cartilage, but it substantially reduces the load the joint absorbs on every stride and restores the muscular shock absorption the joint has been quietly substituting for. A knee that has been paying a tax the hip and glute were supposed to cover often quiets down considerably once those muscles are doing their share again. This is unglamorous work, and it produces results on a timescale of months rather than weeks, but among everything studied for midlife runners' joint pain, progressive strength training has the strongest support.
The peptide conversation belongs downstream of that biomechanical work, as an adjunct rather than a substitute. BPC-157 and TB-500 have been researched, largely in animal models, for tendon and soft-tissue repair mechanisms; GHK-Cu has been studied for its role in extracellular matrix remodeling and collagen synthesis; Cartalax is a short peptide explored for cartilage-related signaling; and growth hormone secretagogues draw interest precisely because they aim at the declining IGF-1 that normally supports cartilage and connective-tissue maintenance. The human evidence for any of these in runners' joint pain is thin and mostly mechanistic, several are research-only compounds rather than approved therapies, and none of them substitute for fixing the load problem underneath. Whether any belongs in a given plan is a question for a prescribing provider who can weigh the individual picture.
What that means for a lifelong runner is that the situation is more open than "wear and tear" suggests. Cartilage matrix, tendon architecture, and neuromuscular load can all be influenced — strength training most of all, with peptides studied only as research-stage adjuncts to that biomechanical work and best discussed with a prescribing provider. The aching joint is reporting a problem worth addressing, not announcing an inevitable decline.
Frequently asked